Compass Therapeutics | Investor Presentation Deck | 20 slides

Compass Therapeutics · 2023-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

6
coverage by narrative range · generated from this deck JSON

Slide inventory

20
every slide · same image gating as the playbook
01
Slide 1
Includes a molecular visualization graphic.front_matter
03
The slide explains the mechanism of action for a bispecific antibody, contrasting single-target blockade with dual-target blockade.present_solution
Open slide detailBeat · Solution
04
The slide outlines a standard Simon 2-stage design, a common statistical framework in oncology trials to allow for early stopping for futility.plan_implementation
Open slide detailBeat · Product
05
The table is split into two columns, both representing the same cohort of 24 patients.analyze_data
Open slide detailBeat · Product
06
The chart is a classic waterfall plot used in oncology clinical trials to demonstrate efficacy.show_traction
Open slide detailBeat · ProductLoop · Cost Of Inaction
07
Clinical trial data visualization showing patient-level progression, response (PR, SD, PD), and status (death, ongoing).show_traction
Open slide detailBeat · ProductLoop · Cost Of Inaction
08
Clinical trial data presentation.show_traction
Open slide detailBeat · ProductLoop · Cost Of Inaction
09
Standard clinical trial survival analysis plots.analyze_data
10
The slide compares clinical trial data for a specific combination therapy against known label safety profiles of individual components.compare_peers
11
Comparison of CTX-009 efficacy metrics (ORR, PFS, OS) against FOLFOX and TOPAZ-1 benchmarks.show_traction
12
The diagram outlines the randomization, treatment regimen, disease progression assessment, and study endpoints.plan_implementation
13
The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment pathways.size_opportunity
Open slide detailBeat · Problem
14
The table highlights Partial Response (PR) rates with a red border, emphasizing clinical activity.analyze_data
Open slide detailBeat · Market Size
15
The slide depicts a standard Simon 2-stage design, a common statistical framework for phase II oncology trials.plan_implementation
Open slide detailBeat · Market Size
16
The slide provides epidemiological data and clinical treatment pathways for CRC, highlighting the limited efficacy of current 3L treatments.establish_context
Open slide detailBeat · Market Size
17
The slide uses a three-column layout to represent distinct clinical study tracks with initiation dates.plan_implementation
Open slide detailLoop · Quick Win Big Bet
18
This appears to be a slide introducing an advisor or team member.other
Open slide detailBeat · Team
19
The table compares a small N=24 study (CTX-009) against larger historical studies (N=81 to N=341).compare_peers
Open slide detailBeat · Competition
20
state_next_steps